… pembrolizumab monotherapy was superior in patients whose tumors express PD-L1 in first-line
R/M HNSCC. Pembrolizumab is … of pembrolizumab monotherapy or pembrolizumab plus …

… In this review we will describe main mechanisms of immunotherapy, immunotherapy drugs
that are approved or under clinical evaluation in head and neck squamous cell carcinoma (…

… in immunotherapy have transformed the practice of oncology. Immunotherapy for treatment
of cancer … interaction directs the development of immunotherapies in head and neck cancer. …

… principles related to head and neck cancer, including the concept of cancer immunosurveillance
and immune escape. Current immunotherapeutic strategies and emerging results from …

… head and neck squamous cell carcinoma (HNSCC), highlighting the potential role for
immunotherapy … This has led to interest in combining immunotherapy with radiation therapy (RT) …

… a DNA-based immunotherapeutic HPV vaccine, … immunotherapeutic vaccine led to induction
of tumor specific immune responses (13). A trial evaluating this targeted immunotherapeutic …

… Cancer immunotherapy is based on modifying the host … For these ends, several immunotherapy
strategies have been … various immunotherapy strategies for head and neck cancer …

… In conclusion, immunotherapy in head and neck cancer is a rapidly evolving field. First
results of clinical trials show evidence of improved efficacy compared to standard …

… with induction chemotherapy, neoadjuvant immunotherapy thus represents an attractive …
the head and neck region, compared to adjuvant immunotherapy, neoadjuvant immunotherapy …

… We summarise current evidence in novel immunotherapeutic approaches in head and
neck cancer and outline future avenues for development in this rapidly evolving field. …